MedTrace Logo

Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation

NCT01472783 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2016-11-16

No results posted yet for this study

Summary

The main purpose of this study is to investigate the effect of veliparib in ovarian cancer patients with known BRCA 1/2 mutations who do no longer respond to conventional chemotherapy.

Conditions

  • Recurrent, Epithelial Ovarian Cancer

Interventions

DRUG

Veliparib

Veliparib (tablet) 300 mg twice daily on days 1-28 of 28 days cycles until progression, unacceptable toxicity or patient refusal.

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Vejle Hospital

    lead OTHER

Principal Investigators

  • Anders Jakobsen, DMSc · Vejle Hospital, Vejle, Denmark

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2016-01-31
Completion
2016-08-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01472783 on ClinicalTrials.gov